Manish Lakhani, MD

The Activated Clotting Time (ACT) Can Be Used to Monitor Enoxaparin and Dalteparin after Intravenous Administration

08/01/2008

A major advance in the use of heparin has been the development of low-molecular weight heparins (LMWH), which inhibit both the action (anti-IIa effect) and the generation (anti-Xa effect) of thrombin.1,2 Because of their ease of...

A major advance in the use of...

08/01/2008

Journal of Invasive Cardiology

Original Contribution

A Novel Point-of-Care Assay for the Monitoring of Low-Molecular Weight Heparins in the Cardiac Catheterization Laboratory

09/15/2008

Jonathan D. Marmur , MD, FACC;

Manish Lakhani , MD;

Erdal Cavusoglu , MD;

Soumaya El Rouby , MD;

ABSTRACT: Background. We designed a study to compare the novel point-of-care assay Hemonox clotting time (Hemonox-CT) with the activated clotting time (ACT) and anti-Xa activity to monitor the anticoagulation effects of enoxaparin and...

ABSTRACT: Background. We...

09/15/2008

Journal of Invasive Cardiology